Skip to main content
    R

    Rani Therapeutics Holdings Inc (RANI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.54
    +0.01 (+2.66%)

    Market Cap: $60.78M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Rani Therapeutics Holdings Inc (RANI) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Rani Therapeutics Holdings (RANI) to earn -$0.17 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.81M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy120.0%
    Buy480.0%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    5

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 2.6%.

    Fiscal year ending Dec 31, 2026
    -$0.17
    EPS consensus, revenue $6.81M
    Fiscal year ending Dec 31, 2027
    -$0.19
    EPS consensus, revenue $6.63M
    Next report
    Mar 25, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.17-$0.18 to -$0.164$6.81M$6.80M to $6.83M3
    Dec 31, 2027-$0.19-$0.20 to -$0.174$6.63MN/A4

    Quarterly Estimates

    The EPS consensus is -$0.05 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.05-$0.06 to -$0.047$1.63MN/A7
    Mar 31, 2027-$0.05-$0.05 to -$0.051N/AN/A1

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 4 upward and 0 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202620
    Fiscal year ending Dec 31, 202720
    Quarter ending Mar 31, 202700

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.18.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.17-$0.17-$0.17-$0.17-$0.18N/A
    Fiscal year ending Dec 31, 2027-$0.19-$0.19-$0.19-$0.19-$0.21N/A

    Frequently Asked Questions About RANI

    What is the RANI stock forecast?

    Consensus analyst estimates put Rani Therapeutics Holdings's EPS at -$0.17 for the fiscal year ending Dec 31, 2026, on revenue of $6.81M. The consensus rating from 5 analysts is Buy.

    How do analysts rate RANI stock?

    Of 5 analysts covering Rani Therapeutics Holdings, 1 rates it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from RANI next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.17, with estimates from -$0.18 to -$0.16 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.19, with estimates from -$0.20 to -$0.17 from 4 analysts.

    What revenue do analysts expect from Rani Therapeutics Holdings next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.81M, with estimates from $6.80M to $6.83M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.63M.

    How many analysts cover RANI?

    5 analysts rate Rani Therapeutics Holdings stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.